Newly Merged dMed-Clinipace Turns Up Heat in China’s Booming CRO Market
Company’s new $50 million funding is the first since its April merger, as competition grows among nation’s contract research organizations (CROs) Key points: dMed-Clinipace’s raises $50 million in the…
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Everest reaches new heights on growing drug sales
1952.HK
